Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect Bellicum Pharmaceuticals to post earnings of ($0.73) per share for the quarter.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the previous year, the firm earned ($0.61) earnings per share. On average, analysts expect Bellicum Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2.86 EPS for the next fiscal year.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) opened at 9.89 on Tuesday. The stock’s market capitalization is $328.61 million. Bellicum Pharmaceuticals, Inc. has a 52 week low of $7.41 and a 52 week high of $23.11. The stock has a 50 day moving average price of $10.95 and a 200 day moving average price of $11.26.

BLCM has been the subject of a number of research analyst reports. Raymond James Financial, Inc. set a $18.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. BidaskClub cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 target price (down from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. Finally, ValuEngine cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $26.20.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.